Entera Bio Stock

Entera Bio Cash Conversion

The Cash Conversion Rate (OCF/Net Income) of Entera Bio (ENTX) as of Aug 14, 2026 is 64.43 %. In the previous year, Cash Conversion Rate (OCF/Net Income) was 71.46 % — a change of -9.84% (lower).

Cash Conversion

64.43 %

YoY

-9.84%

Last updated:

Cash Conversion Rate (OCF/Net Income) of Entera Bio is 2026 64.43 % . Cash Conversion Rate (OCF/Net Income) of Entera Bio was 2025 71.46 % . It decreases by -9.84% lower compared to the previous year.
Access this data via the Eulerpool API

Entera Bio Stock analysis

What does Entera Bio do? Entera Bio Ltd is an emerging biotechnology company focused on developing oral medications to treat unmet medical needs. The company was founded in 2010 and is headquartered in Jerusalem, Israel. Its history began with the discovery of the "EnteraGam" molecule in the intestinal cells of breastfed infants, which helps them fight infections. This led to the development of EnteraGam for the treatment of various autoimmune diseases. The company's business model is based on developing oral formulations for existing drugs and discovering and developing new molecules. Its focus areas are osteoporosis, hypoparathyroidism, chronic kidney disease, and autoimmune diseases. Entera Bio is divided into three business divisions: the Oral Protein Delivery Platform, the Oral Parathyroid Hormone (PTH) Platform, and the Collagen-based Platform for Wound Healing. Its products include EB611, a candidate for hypoparathyroidism treatment, EB613 for osteoporosis treatment, and EB612 for chronic kidney disease. These products have potential to improve the lives of millions of patients worldwide. Entera Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Entera Bio stock

Cash Conversion Rate (OCF/Net Income) of Entera Bio is 64.43 % in 2026.

Cash Conversion Rate (OCF/Net Income) of Entera Bio changed from 71.46 % to 64.43 %, representing a -9.84% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Rate (OCF/Net Income) Entera Bio since 2006 – with annual values, charts, and detailed analysis.

Cash conversion measures how effectively net income converts to operating cash flow. Ratios above 100% indicate high-quality, cash-backed earnings.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Rate (OCF/Net Income)'s Entera Bio with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Rate (OCF/Net Income)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Rate (OCF/Net Income).

Access this data via the Eulerpool API

Cash Flow — Entera Bio

All Key Metrics — Entera Bio